ReviewEukaryotic cell2011
Modulation of morphogenesis in Candida albicans by various small molecules.
Review in Eukaryotic cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.
- Does the ketogenic diet improve neurological disorders by influencing gut microbiota? A systematic review.Nutrition journal · 2023Pooled it
- Fungal biofilm formation and quorum sensing: Regulatory mechanisms and control strategies.World journal of microbiology & biotechnology · 2026Review
- Acridine Derivatives as Antifungal and Antivirulence Agents AgainstInternational journal of molecular sciences · 2025Article
- Synergistic anti-biofilm strategy based on essential oils and its application in the food industry.World journal of microbiology & biotechnology · 2025Review
- Natural Source-Derived Compounds with Antifungal Activity Against Medically Relevant Fungi.Infection and drug resistance · 2025Review
- An experimental approach to study foraging memory in ectomycorrhizal mycelium.Communicative & integrative biology · 2025Article
- Antibiofilm activity of silver nanoparticles against Candida sp. isolated from the oral cavity.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- Anti-virulence strategy of diaryl chalcogenide compounds againstVirulence · 2023Article
- Unexpected Inhibitory Effect of Octenidine Dihydrochloride onAntibiotics (Basel, Switzerland) · 2023Article
- K-aurein: A notable aurein 1.2-derived peptide that modulates Candida albicans filamentation and reduces biofilm biomass.Amino acids · 2023Article
- 2,4-Diacetylphloroglucinol ModulatesJournal of fungi (Basel, Switzerland) · 2022Article
- Continuing Shifts in Epidemiology and Antifungal Susceptibility Highlight the Need for Improved Disease Management of Invasive Candidiasis.Microorganisms · 2022Review
- Lectins ConA and ConM extracted from Canavalia ensiformis (L.) DC and Canavalia rosea (Sw.) DC inhibit planktonic Candida albicans and Candida tropicalis.Archives of microbiology · 2022Article
- Alternative Treatment Strategies for Secondary Bacterial and Fungal Infections Associated with COVID-19.Infectious diseases and therapy · 2022Review
- CouldJournal of clinical medicine · 2022Review
- Ketoconazole resistant Candida albicans is sensitive to a wireless electroceutical wound care dressing.Bioelectrochemistry (Amsterdam, Netherlands) · 2021Article
- Transcriptional response of Candida albicans to Pseudomonas aeruginosa in a polymicrobial biofilm.G3 (Bethesda, Md.) · 2021Article
- Antifungal activity of hypocrellin compounds and their synergistic effects with antimicrobial agents against Candida albicans.Microbial biotechnology · 2021Article
- Article
- Uncharted territories in the discovery of antifungal and antivirulence natural products from bacteria.Computational and structural biotechnology journal · 2021Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenic yeast Candida albicans, a member of the mucosal microbiota, is responsible for a large spectrum of infections, ranging from benign thrush and vulvovaginitis in both healthy and immunocompromised individuals to severe, life-threatening infections in immunocompromised patients. A striking feature of C. albicans is its ability to grow as budding yeast and as filamentous forms, including hyphae and pseudohyphae. The yeast-to-hypha transition contributes to the overall virulence of C. albicans and may even constitute a target for the development of antifungal drugs. Indeed, impairing morphogenesis in C. albicans has been shown to be a means to treat candidiasis. Additionally, a large number of small molecules such as farnesol, fatty acids, rapamycin, geldanamycin, histone deacetylase inhibitors, and cell cycle inhibitors have been reported to modulate the yeast-to-hypha transition in C. albicans. In this minireview, we take a look at molecules that modulate morphogenesis in this pathogenic yeast. When possible, we address experimental findings regarding their mechanisms of action and their therapeutic potential. We discuss whether or not modulating morphogenesis constitutes a strategy to treat Candida infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.